MT-303
- Generic Name
- MT-303
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Myeloid Therapeutics
- Target Recruit Count
- 48
- Registration Number
- NCT06478693
- Locations
- 🇦🇺
St Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺Integrated Clinical Oncology Network (ICON) Pty Ltd, Woolloongabba, Queensland, Australia
🇦🇺The Alfred Hospital, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath